心脏术后休克患者ECMO期间出血与血栓事件
该回顾性研究纳入152例心脏术后休克接受ECMO的患者,分析抗凝治疗对出血和血栓风险的影响。结果显示33例(23%)发生40次血栓事件,64例(45%)发生86次出血事件。抗凝治疗可减少血栓栓塞事件,但当活化部分凝血活酶时间大于60秒时,出血风险可能超过获益。
要点
- 抗凝治疗与血栓风险降低相关(OR 0.39;95%CI 0.19-0.79)
- APTT大于60秒时出血风险增加(OR 2.32;95%CI 1.14-4.73)
- 心脏术后休克ECMO患者出血事件发生率高于血栓事件
核心结论
- 抗凝治疗可减少心脏术后休克ECMO患者的血栓栓塞事件,但APTT大于60秒时出血风险可能超过获益。
研究设计与样本
- 回顾性研究,纳入2007年7月至2019年7月因心脏术后休克接受ECMO的152例患者,采用多水平逻辑回归评估危险因素。
主要发现
- 152例患者中33例(23%)发生40次血栓事件,64例(45%)发生86次出血事件。
- 出血预测因素包括术中输注浓缩红细胞(OR 1.05;95%CI 1.01-1.09)、输注血小板(OR 1.10;95%CI 1.05-1.16)、INR(OR 1.18;95%CI 1.02-1.37)及APTT大于60秒(OR 2.32;95%CI 1.14-4.73)。
- 血栓预测因素包括使用抗凝药(OR 0.39;95%CI 0.19-0.79)、外科排气(OR 3.07;95%CI 1.29-7.31)、血红蛋白(OR 1.38;95%CI 1.06-1.79)及中心插管(OR 2.06;95%CI 1.03-4.11)。
- 未接受抗凝治疗患者每日血栓预测概率在0.075至0.038之间,接受抗凝治疗且APTT在25至80秒之间时降至0.030至0.013之间。
临床怎么用
- 心脏术后休克患者ECMO期间应个体化抗凝管理,监测APTT,避免超过60秒以降低出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticoagulation therapy management during venoarterial extracorporeal membrane oxygenation (ECMO) is particularly difficult in postcardiotomy shock patients given a significant bleeding risk. We sought to determine the effect of anticoagulation treatment on bleeding and thrombosis risk for postcardiotomy shock patients on ECMO. METHODS: We retrospectively reviewed patients who received ECMO for postcardiotomy shock from July 2007 through July 2019. Characteristics of patients who had bleeding and thrombosis were investigated, and risk factors were assessed by multilevel logistic regression. RESULTS: Of the 152 patients who received ECMO for postcardiotomy shock, 33 (23%) had 40 thrombotic events and 64 (45%) had 86 bleeding events. Predictors of bleeding were intraoperative packed red blood cell transfusion (odds ratio [OR] 1.05; 95% confidence interval [CI], 1.01 to 1.09), platelet transfusion (OR 1.10; 95% CI, 1.05 to 1.16), international normalized ratio (OR 1.18; 95% CI, 1.02 to 1.37), and activated partial thromboplastin time greater than 60 seconds (OR 2.32; 95% CI, 1.14 to 4.73). Predictors of thrombosis were anticoagulant use (OR 0.39; 95% CI, 0.19 to 0.79), surgical venting (OR 3.07; 95% CI, 1.29 to 7.31), hemoglobin (OR 1.38; 95% CI, 1.06 to 1.79), and central cannulation (OR 2.06; 95% CI, 1.03 to 4.11). The daily predicted probability of thrombosis was between 0.075 and 0.038 for patients who did not receive anticoagulation and decreased to between 0.030 and 0.013 for patients who received anticoagulation treatment at activated partial thromboplastin times between 25 and 80 seconds. CONCLUSIONS: Anticoagulation therapy can reduce thromboembolic events in postcardiotomy shock patients on ECMO, but bleeding risk may outweigh this benefit at activated partial thromboplastin times greater than 60 seconds.
引用
- Melehy A, Ning Y, Kurlansky P, et al. Bleeding and Thrombotic Events During Extracorporeal Membrane Oxygenation for Postcardiotomy Shock. Ann Thorac Surg. 2021. PMID: 33609547. doi:10.1016/j.athoracsur.2021.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。